"Mechanick\u00E1 srde\u010Dn\u00ED podpora CentriMag (Levitronix LLC, Waltham, USA) je ur\u010Dena pro kr\u00E1tkdobou parakorpor\u00E1ln\u00ED podporu ob\u011Bhu u pacient\u016F v refraktern\u00EDm kardiogenn\u00EDm \u0161oku. V tomto sd\u011Blen\u00ED shrnujeme na\u0161e zku\u0161enosti s t\u00EDmto syst\u00E9mem umo\u017E\u0148uj\u00EDc\u00EDm urgentn\u00ED zaveden\u00ED levostrann\u00E9, pravostrann\u00E9 i oboustrann\u00E9 podpory ob\u011Bhu. Od prosince 2007 do prosince 2010 jsme Cetrimag implantovali u 20 pacient\u016F ( z toho 3 \u017Eeny). Pr\u016Fm\u011Brn\u00FD v\u011Bk pacient\u016F byl 46,5 +- 12,0 rokuz (od 25 do 67 let). Ind\u00EDikac\u00ED pro implantaci podpory byl kardiogenn\u00ED \u0161ok u pacient\u016F: s refraktern\u00EDm srde\u010Dn\u00EDm selh\u00E1n\u00EDm v kone\u010Dn\u00E9m stadiu (13 pacient\u016F - sedmkr\u00E1t ischemick\u00E1 choroba srde\u010Dn\u00ED, \u010Dty\u0159ikr\u00E1t dilatovan \u00E1 kardiomyopatie, dvakr\u00E1t myokarditida), s postkardiotomick\u00FDm srde\u010Dn\u00EDm selh\u00E1n\u00ED (t\u0159i pacienti), se selh\u00E1n\u00EDm \u0161t\u011Bpu po transplantaci srdce (t\u0159i pacienti) a pravostrann\u00FDm selh\u00E1n\u00EDm po implantaci dlouhodob\u00E9 levostrann\u00E9 podpory HeartMate II (jeden pacient).Pr\u016Fm\u011Brn\u00E1 doba podpory byla 25,3 +- 16,5 dne (od 5 do 71 dn\u016F), U swdmi (35%) pacient\u016F byla podpora ukon\u010Dena transplantac\u00ED srdce. K obnoven\u00ED funkce srdce do\u0161lo u p\u011Bti (25%) pacient\u016F, u jednoho (5%) pacienta jsme implantovali dlouhodobou levostrannou podporu HeartMate II, sedm (35%) pacient\u016F b\u011Bhem podpory zem\u0159elo. T\u0159\u010Dicetidenn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED bylo 70 % (14 pacient\u016F), t\u0159\u00EDm\u011Bs\u00ED\u010Dn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED bylo 60% (12 pacient\u016F). Pr\u016Fm\u011Brn\u00E1 doba od implantace podpory k za\u0159azen\u00ED na listinu \u010Dekatel\u016F na transplantace srdce byla 13,4 + 20,5 dne (od 0 do 57 dn\u00ED), v z\u00E1vislosti na \u00FAprav\u011B org\u00E1nov\u00FDch funkc\u00ED, v\u010Detn\u011B CNS. Pr\u016Fm\u011Brn\u00E1 \u010Dekac\u00ED doba byla 14,6 +- 11,3 (od 3 do 35 dn\u00ED). T\u0159\u00EDm\u011Bs\u00ED\u010Dn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED po transplantaci srdce bylo 100%, jednoro\u010Dn\u00ED 71% (p\u011Bt ze sedmi pacient\u016F).Zaveden\u00EDm syst\u00E9mu Levitronix Centrimag na na\u0161em pracovi\u0161ti do\u0161\u011Blo k v\u00FDrazn\u00E9mu zlep\u0161en\u00ED jinak infaustn\u00ED progn\u00F3zy u pacient\u016F,jejich\u017E p\u0159edpokl\u00E1dan\u00E9 p\u0159e\u017E\u00EDv\u00E1n\u00ED bez urgentn\u00ED implantace mechanick\u00E9 srde\u010Dn\u00ED porpory bylo v \u0159\u00E1du hodin, maxim\u00E1ln\u011B n\u011Bkolika dn\u016F." . "53" . "RIV/00209775:_____/11:#0000215" . "CZ - \u010Cesk\u00E1 republika" . "Kr\u00E1tkodob\u00E1 mechanick\u00E1 srde\u010Dn\u00ED podpora centrifug\u00E1ln\u00ED pumpou Levitronix Centrimag"@cs . "Short-term mechanical support with the Levitronix CentriMag centrifugal pump"@en . . . "0010-8650" . . . "Kr\u00E1tkodob\u00E1 mechanick\u00E1 srde\u010Dn\u00ED podpora centrifug\u00E1ln\u00ED pumpou Levitronix Centrimag"@cs . . "Kr\u00E1tkodob\u00E1 mechanick\u00E1 srde\u010Dn\u00ED podpora centrifug\u00E1ln\u00ED pumpou Levitronix Centrimag" . . . . . "4"^^ . "RIV/00209775:_____/11:#0000215!RIV12-MZ0-00209775" . "Kr\u00E1tkodob\u00E1 mechanick\u00E1 srde\u010Dn\u00ED podpora centrifug\u00E1ln\u00ED pumpou Levitronix Centrimag" . . "Ondr\u00E1\u0161ek, Ji\u0159\u00ED" . . . "The mechanical support device (Levitronix LLC, Waltham, USA) is inended for short-term paracorporeal circulatory support in patients in refractory shock. The paper presents our experience with the device allowing for urgent initiationof left, or biventricular circulatory support. From December 2007 trough December 2010, the CentriMag device was implanted in 20 (3 women) od our patients. The mean age of our patients was 46.5 +- 12.0 years (range, 25-67 years) Indications for device implantation included cardiogenic shok in patients with refractory end-stage heart failure (13 patient with coronary heart disease in seven; dilated cardiomyopathy infour, and myocarditis in two), postcardiotomy heart failure (three), heart transplant failure (three), and right-heart failure following the implantaion of the HeartMate II left ventricular assist device (one patient).The mean ventricular support time was 25.3 +- 16.5 days (range, 5-71 days). In seven patients (35%), mechanical support was completed with heart transplantation. Recovery of heart function occured in five (25%) patients. The HeartMate II long-term left ventricular assist device was implanted in one (5%) patient. Seven (35%) patients died while on the support device. The 30-day and three-month survival rates were 70% (14 patients), respectively. The mean time from support device implantation to putting zhe patient on the waiting list was 13.4 +-* 20.5 days (range, 0-57 days( depending on recovery of organ (including the CNS) function.The mean waiting time was 14.6 +- 11.3 days). The three-month and one-yeart survival rates after heart transplantation were 100% and 71% (5 of 7 patients), respectively. The installation of the Levitronix CentriMag device in our center resulted in a marked imrpovement of an otherwise grim prognosis of patients whose anticipated survival rates, unless undergoing urgent mechanical cardiac support implantation, would be in the order of hours, or several days at most."@en . "3" . . "http://e-coretvasa.cz" . "N\u011Bmec, Petr" . . "Horv\u00E1th, Vladim\u00EDr" . . "208365" . "Short-term mechanical support with the Levitronix CentriMag centrifugal pump"@en . "Bettincov\u00E1, Anita" . "Pokorn\u00FD, Petr" . "mechanical cardiac support; cardiogenic shock; end-stage heart failure; CentriMag device; bridge-to-transplantation"@en . . . "Cor et vasa" . "7"^^ . "[9F6C966A89CF]" . . . . "Pavl\u00EDk, Petr" . "Mechanick\u00E1 srde\u010Dn\u00ED podpora CentriMag (Levitronix LLC, Waltham, USA) je ur\u010Dena pro kr\u00E1tkdobou parakorpor\u00E1ln\u00ED podporu ob\u011Bhu u pacient\u016F v refraktern\u00EDm kardiogenn\u00EDm \u0161oku. V tomto sd\u011Blen\u00ED shrnujeme na\u0161e zku\u0161enosti s t\u00EDmto syst\u00E9mem umo\u017E\u0148uj\u00EDc\u00EDm urgentn\u00ED zaveden\u00ED levostrann\u00E9, pravostrann\u00E9 i oboustrann\u00E9 podpory ob\u011Bhu. Od prosince 2007 do prosince 2010 jsme Cetrimag implantovali u 20 pacient\u016F ( z toho 3 \u017Eeny). Pr\u016Fm\u011Brn\u00FD v\u011Bk pacient\u016F byl 46,5 +- 12,0 rokuz (od 25 do 67 let). Ind\u00EDikac\u00ED pro implantaci podpory byl kardiogenn\u00ED \u0161ok u pacient\u016F: s refraktern\u00EDm srde\u010Dn\u00EDm selh\u00E1n\u00EDm v kone\u010Dn\u00E9m stadiu (13 pacient\u016F - sedmkr\u00E1t ischemick\u00E1 choroba srde\u010Dn\u00ED, \u010Dty\u0159ikr\u00E1t dilatovan \u00E1 kardiomyopatie, dvakr\u00E1t myokarditida), s postkardiotomick\u00FDm srde\u010Dn\u00EDm selh\u00E1n\u00ED (t\u0159i pacienti), se selh\u00E1n\u00EDm \u0161t\u011Bpu po transplantaci srdce (t\u0159i pacienti) a pravostrann\u00FDm selh\u00E1n\u00EDm po implantaci dlouhodob\u00E9 levostrann\u00E9 podpory HeartMate II (jeden pacient).Pr\u016Fm\u011Brn\u00E1 doba podpory byla 25,3 +- 16,5 dne (od 5 do 71 dn\u016F), U swdmi (35%) pacient\u016F byla podpora ukon\u010Dena transplantac\u00ED srdce. K obnoven\u00ED funkce srdce do\u0161lo u p\u011Bti (25%) pacient\u016F, u jednoho (5%) pacienta jsme implantovali dlouhodobou levostrannou podporu HeartMate II, sedm (35%) pacient\u016F b\u011Bhem podpory zem\u0159elo. T\u0159\u010Dicetidenn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED bylo 70 % (14 pacient\u016F), t\u0159\u00EDm\u011Bs\u00ED\u010Dn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED bylo 60% (12 pacient\u016F). Pr\u016Fm\u011Brn\u00E1 doba od implantace podpory k za\u0159azen\u00ED na listinu \u010Dekatel\u016F na transplantace srdce byla 13,4 + 20,5 dne (od 0 do 57 dn\u00ED), v z\u00E1vislosti na \u00FAprav\u011B org\u00E1nov\u00FDch funkc\u00ED, v\u010Detn\u011B CNS. Pr\u016Fm\u011Brn\u00E1 \u010Dekac\u00ED doba byla 14,6 +- 11,3 (od 3 do 35 dn\u00ED). T\u0159\u00EDm\u011Bs\u00ED\u010Dn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED po transplantaci srdce bylo 100%, jednoro\u010Dn\u00ED 71% (p\u011Bt ze sedmi pacient\u016F).Zaveden\u00EDm syst\u00E9mu Levitronix Centrimag na na\u0161em pracovi\u0161ti do\u0161\u011Blo k v\u00FDrazn\u00E9mu zlep\u0161en\u00ED jinak infaustn\u00ED progn\u00F3zy u pacient\u016F,jejich\u017E p\u0159edpokl\u00E1dan\u00E9 p\u0159e\u017E\u00EDv\u00E1n\u00ED bez urgentn\u00ED implantace mechanick\u00E9 srde\u010Dn\u00ED porpory bylo v \u0159\u00E1du hodin, maxim\u00E1ln\u011B n\u011Bkolika dn\u016F."@cs . . "Slav\u00EDk, Ji\u0159\u00ED" . . . "7"^^ . "V" .